Skip to main content

Table 1 Patient characteristics

From: Rapid reconstitution of CD4 T cells and NK cells protects against CMV-reactivation after allogeneic stem cell transplantation

  Total Reactivation p valuea
Total (%) CMV only EBV only CMV and EBV
Number of patients 116 54 (47) 36 9 9  
Sex
 M 71 30 (42) 18 8 4 0.26
 F 45 24 (53) 18 1 5
Median age (range) 49.8 (17.6–70.6) 50.7 (17.6–68.5) 55.7 (28.5–68.5) 55.8 (17.5–68.3) 56.8 (23.8–65.8) 0.43
Stemcell source
 Cord blood 1 0 (0) 0 0 0 0.30
 Peripheral blood 106 48 (45) 34 6 7
 Bone marrow 9 6 (67) 2 3 2
Donor
 Related 35 13 (37) 11 1 2 0.23
 Unrelated 81 40 (5) 25 8 7
 HLA mismatch 20 11 (55) 7 2 2
Conditioning
 NMA 106 50 (47) 36 6 8 0.47
 MA 10 4 (40) 0 2 2
 ATG 87 46 (53) 28 9 9 0.03
EBV serology (R/D)
 +/+ 94 42 (45) 27 8 7 0.84
 +/− 5 3 (60) 1 0 2
 −/+ 4 2 (50) 2 0 0
 −/− 11 6 (54) 5 1 0
CMV serology (R/D)
 +/+ 39 28 (72) 24 0 4 <10 −4
 +/− 37 18 (49) 10 5 3
 −/+ 10 2 (20) 1 0 1
 −/− 28 5 (18) 1 4 0
aGVHD
 Yes 64 29 (44) 17 5 7 0.83
 No information 19 9 (47) 8 1 0
 Relapse 14 7 (50) 2 0 0 0.78
Viral loadb
 Low (<1000 copies/ml) NA 28 (52) 21 4 3 NA
 High (>1000 copies/ml) NA 26 (48) 15 5 6
  1. ATG anti-thymocyte globulin; EBV Epstein-Barr virus; CMV cytomegalovirus; R/D recipient/donor; aGVHD acute graft versus host disease; NA non-applicable
  2. aComparison between reactivation and no reactivation group: unpaired t test for age, univariate analysis using Fisher’s Exact test
  3. bPatients were categorized in reactivation categories based on their peak viral load of either EBV and/or CMV DNA in plasma during 6 months post-SCT